KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Novavax (NVAX) over the last 13 years, with Q3 2025 value amounting to $9.2 million.

  • Novavax's Non Operating Income fell 4235.65% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.3 million, marking a year-over-year increase of 1561.72%. This contributed to the annual value of $40.4 million for FY2024, which is 671.84% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Non Operating Income is $9.2 million, which was down 4235.65% from $11.9 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Non Operating Income ranged from a high of $64.0 million in Q4 2022 and a low of -$34.8 million during Q3 2022
  • For the 5-year period, Novavax's Non Operating Income averaged around $6.0 million, with its median value being $5.5 million (2023).
  • The largest annual percentage gain for Novavax's Non Operating Income in the last 5 years was 1463986.18% (2022), contrasted with its biggest fall of 75630.78% (2022).
  • Quarter analysis of 5 years shows Novavax's Non Operating Income stood at $434000.0 in 2021, then skyrocketed by 14639.86% to $64.0 million in 2022, then crashed by 82.83% to $11.0 million in 2023, then grew by 19.58% to $13.1 million in 2024, then tumbled by 30.13% to $9.2 million in 2025.
  • Its last three reported values are $9.2 million in Q3 2025, $11.9 million for Q2 2025, and $10.1 million during Q1 2025.